Advances in Low-Vision Research

New technologies and initiatives are improving quality of life for these patients.

By Susan L. Worley, contributing writer

Faricimab Shows Potential for 16-Week Dosing

Initial data presented from Genentech’s STAIRWAY study.

Surgical Management of Proliferative Diabetic Retinopathy

Considerations and treatment approaches.

New Insight Into Obstructive Sleep Apnea and Diabetic Retinopathy

Treating OSA may stop or reverse retinal disease progression.

Decision Making in Diabetic Retinopathy Treatment

A variety of tools enable individualized care.

Imaging Diabetic Patients With Swept-Source Optical Coherence Tomography

Key advantages for the patient and practice.

Subthreshold Laser Treatment of Retinal Diseases

A potential alternative for treating center-involving macular edema.

UPFRONT: Giving Context to the Data

SUBSPECIALTY NEWS: Sustained-release drug, 12-week dosing, and more.

CODING Q&A: Clarity Comes to Modifier 24

What defines an unrelated procedure?

CLINICAL TRIAL DOWNLOAD: Discussing New Abicipar Pegol Data

Experts explore 12-week dosing and inflammation rates.

RETINA CONVERSATIONS: A Conversation With Thomas A. Ciulla, MD, MBA

A journey from academia to the corporate world.

UVEITIS CORNER: Applications of OCT Angiography in Uveitis

A useful tool for retina specialists to diagnose and monitor disease.

Roche Begins Phase 3 for Sustained-Release Ranibizumab

NEW PRODUCT APPLICATIONS: The Perfect Pairing of UWF and OCT

Ultrawidefield imaging combined with optical coherence tomography provide superior imaging.

CLINICAL TRIAL UPDATE

Making History

Exploring Luxturna gene therapy and its surgical delivery

What Are We Missing?

Steps for developing an educational program to help reduce missed amd diagnoses

All the Right Moves

If putting down roots means relocating your practice, here are some tips for a smooth transition

MARKETING MATTERS

Connecting with Your Community

CODING CORNER

Coding Reassessment for Complex Retinal Detachment Repair